Drug Type Fc fusion protein, Biosimilar |
Synonyms Etanercept biosimilar, Nanercept |
Target |
Action inhibitors |
Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Vietnam (01 Jan 2019), |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Psoriasis | Vietnam | 01 Jan 2019 | |
| Rheumatoid Arthritis | Vietnam | 01 Jan 2019 |
Not Applicable | 2,030 | ETA-treated patients who switched to SB4 | vecgoltgcu(flromhrcoo) = gyoayptlyt ijcmxrmtuk (gdhccstlqi ) | - | 06 Nov 2017 |






